Article

Absorption of clonazepam after intranasal and buccal administration.

Department of Clinical Pharmacy and Toxicology, Maasland Hospital, Sittard, The Netherlands.
British Journal of Clinical Pharmacology (Impact Factor: 3.69). 05/1995; 39(4):449-51. DOI: 10.1111/j.1365-2125.1995.tb04476.x
Source: PubMed

ABSTRACT Serum concentrations of clonazepam after intranasal, buccal and intravenous administration were compared in a cross-over study in seven healthy male volunteers. Each subject received a 1.0 mg dose of clonazepam intranasally and buccally and 0.5 mg intravenously. A Cmax of 6.3 +/- 1.0 ng ml-1 (mean; +/- s.d.) was measured 17.5 min (median) (range 15-20 min) after intranasal administration. A second peak (4.6 +/- 1.3 ng ml-1) caused by oral absorption was seen after 1.7 h (range 0.7-3.0 h). After buccal administration a Cmax of 6.0 +/- 3.0 ng ml-1 was measured after 50 min (range 30-90 min) with a second peak of 6.5 +/- 2.5 ng ml-1 after 3.0 h (range 2.0-4.0 h). Two minutes after i.v. injection of 0.5 mg clonazepam the serum concentration was 27 +/- 18 ng ml-1. It is concluded that intranasal clonazepam is an alternative to buccal administration. However, the Cmax of clonazepam after intranasal administration is not high enough to recommend the intranasal route as an alternative to intravenous injection.

1 Bookmark
 · 
425 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ritodrine hydrochloride (RD-HCl) tablets containing alginate (AL) and lactose (LC) with or without microcrystalline (MC) as excipients were produced as a buccal dosage form. The RD-HCl (2mg) tablets with AL/LC but no MC swelled and dissolved gradually in the in vitro dissolution test. The tablet showing the fastest dissolution and highest drug release rate, called Tablet A1, was selected as a tablet to show rapid and prolonged absorption. However, in the in vivo buccal absorption test using rats, it could not give a plasma concentration over the human minimal effective level (15ng/ml). The modified tablet containing AL, LC, MC and RD-HCl (4mg), named Tablet B/MC, showed better hardness and faster drug release. Tablet B/MC gave a plasma concentration over the human effective level within 15min, and the plasma concentration was maintained at >15ng/ml over 4h. Moreover, the deconvolution analyses demonstrated that a prolonged high plasma levels could be achieved in vivo best with Tablet B/MC. Tablet B/MC improved the pharmacokinetic profile in comparison with Tablet A1 and the solution dosage form. The RD-HCl buccal tablets with AL, LC and MC as excipients are suggested to be possibly useful for the treatment of premature labor.
    International Journal of Pharmaceutics 04/2014; · 3.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Although ritodrine (RD)-hydrochloride (HCl), named RD-HCl, is widely used in the treatment of premature labor by intravenous prolonged infusion or frequent oral dosing of tablets, those administrations often lower patients' quality of life (QOL) or cause undesirable side effects, such as tachycardia; therefore, in this study, the potential usefulness of buccal administration as a novel administration method was examined in vivo. Method: First, the HPLC method was assessed for the determination of plasma RD concentration. Then, after RD-HCl solution in saline was administered intravenously (1 mg/kg), intragastrically (10 mg/kg) or buccally (10 mg/kg) in rats, the plasma concentration-time profiles were investigated, and the absorption extent and rate compared. Results: The present modified determination method by HPLC with fluorescence detection (Ex. 278 nm, Em. 306 nm) was suitable to analyze the plasma level at 8-200 ng/mL. Buccal administration gave the best plasma concentration-time profile for maintenance of an effective plasma level and fewer side effects. Absorption rates calculated by deconvolution also supported better sustained absorption in buccal dosing. Conclusion: Buccal application of RD-HCl was demonstrated to be a potentially useful dosing method in the treatment of premature labor with RD-HCl.
    Drug Development and Industrial Pharmacy 07/2012; · 1.54 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Koelewijn M, Wanrooij BS. Als de patiënt niet meer kan slikken… Huisarts Wet 2006;49(10):519-24. In dit artikel bespreken we de problemen die kunnen ontstaan als een patiënt in de laatste fase van zijn leven niet meer kan slikken. Achtereenvolgens staan we stil bij vragen over uitdroging, het belang van goede mondverzorging en de mogelijkheden om noodzakelijke medicatie toe te dienen als het langs orale weg niet meer gaat. Van een aantal veelgebruikte medicijnen in deze fase komen vooral de subcutane, transdermale, rectale en transmucosale toedieningswijze aan de orde. Aan de hand van een casus laten we zien dat het de kwaliteit van leven van de patiënt kan bevorderen als de huisarts al in een eerder stadium in de palliatieve fase de medicatie herziet en alternatieve manieren van toediening overweegt. darmaandoening-farmacotherapie-mondaandoeningen-palliatieve zorg-terminale zorg
    Huisarts en wetenschap 01/2006; 49(10):728-735.

Full-text (2 Sources)

Download
66 Downloads
Available from
Jun 2, 2014